Premium
Measurement of ceftazidime concentration in human plasma by ultra‐performance liquid chromatography–tandem mass spectrometry. Application to critically ill patients and patients with osteoarticular infections
Author(s) -
RigoBonnin Raül,
CoboSacristán Sara,
Padullés Ariadna,
Ribera Alba,
ArbiolRoca Ariadna,
Murillo Óscar,
SabaterRiera Joan,
Alía Pedro
Publication year - 2016
Publication title -
biomedical chromatography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 65
eISSN - 1099-0801
pISSN - 0269-3879
DOI - 10.1002/bmc.3563
Subject(s) - chemistry , chromatography , critically ill , liquid chromatography–mass spectrometry , mass spectrometry , tandem mass spectrometry , ceftazidime , intensive care medicine , medicine , bacteria , biology , pseudomonas aeruginosa , genetics
Ceftazidime is an antibiotic belonging to the third generation of the cephalosporin family. It is indicated in the treatment of serious, simple or mixed bacterial infections, and its administration in continuous or intermittent infusion allows optimization of the concentration of antibiotic to keep it above the minimum inhibitory concentration. We developed and validated a chromatographic method by ultra‐performance liquid chromatography–tandem mass spectrometry to measure ceftazidime concentration in human plasma. Following extraction with acetonitrile and 1,2‐dichloroethane, the chromatographic separation was achieved using an Acquity ® UPLC ® BEH TM (2.1 × 100 mm i.d., 1.7 µm) reverse‐phase C 18 column, with a water–acetonitrile linear gradient containing 0.1% formic acid at a 0.4 mL/min flow rate. Ceftazidime and its internal standard (cefotaxime) were detected by electrospray ionization mass spectrometry in positive ion multiple reaction monitoring mode using mass‐to‐charge transitions of 547.0 → 467.9/396.1 and 456.0 → 395.8/324.1, respectively. The limit of quantification was 0.58 mg/L and linearity was observed in the range 0.58–160 mg/L. Coefficients of variation and absolute relative biases were <9.8 and 8.4%. The mean recovery for ceftazidime was 74.4 ± 8.1%. Evaluation of the matrix effect showed ion enhancement, and no carry‐over was observed. The validated method could be applied to daily clinical laboratory practice to measure the concentration of ceftazidime in plasma. Copyright © 2015 John Wiley & Sons, Ltd.